441 related articles for article (PubMed ID: 31619220)
1. Medullary thyroid carcinoma with double negative calcitonin and CEA: a case report and update of literature review.
Gambardella C; Offi C; Clarizia G; Romano RM; Cozzolino I; Montella M; Di Crescenzo RM; Mascolo M; Cangiano A; Di Martino S; Candela G; Docimo G
BMC Endocr Disord; 2019 Oct; 19(1):103. PubMed ID: 31619220
[TBL] [Abstract][Full Text] [Related]
2. Calcitonin negative Medullary Thyroid Carcinoma: a challenging diagnosis or a medical dilemma?
Gambardella C; Offi C; Patrone R; Clarizia G; Mauriello C; Tartaglia E; Di Capua F; Di Martino S; Romano RM; Fiore L; Conzo A; Conzo G; Docimo G
BMC Endocr Disord; 2019 May; 19(Suppl 1):45. PubMed ID: 31142313
[TBL] [Abstract][Full Text] [Related]
3. Prognostic variables and calcitonin in medullary thyroid cancer.
Clark JR; Fridman TR; Odell MJ; Brierley J; Walfish PG; Freeman JL
Laryngoscope; 2005 Aug; 115(8):1445-50. PubMed ID: 16094121
[TBL] [Abstract][Full Text] [Related]
4. Disparity between tissue and serum calcitonin and carcinoembryonic antigen in a patient with medullary thyroid carcinoma.
Alapat DV; Ain KB; Sloan DA; Monaghan KG; Karabakhtsian RG
Endocrine; 2011 Apr; 39(2):148-52. PubMed ID: 21243446
[TBL] [Abstract][Full Text] [Related]
5. [Medullary thyroid carcinoma].
Tiedje V; Ting S; Dralle H; Schmid KW; Führer D
Internist (Berl); 2015 Sep; 56(9):1019-31. PubMed ID: 26338063
[TBL] [Abstract][Full Text] [Related]
6. High CEA levels in a case of resected colorectal cancer: delayed diagnosis of metachronous medullary thyroid cancer.
Chen SW; Chen YK
World J Surg Oncol; 2017 Dec; 15(1):230. PubMed ID: 29284496
[TBL] [Abstract][Full Text] [Related]
7. [Usefulness of serum calcitonin, CEA and AFP assays in the early detection of medullary thyroid carcinoma relapse].
Łacka K; Michałek K; Majewski P
Wiad Lek; 2002; 55(7-8):394-403. PubMed ID: 12428567
[TBL] [Abstract][Full Text] [Related]
8. Brain metastasis from calcitonin-negative medullary thyroid carcinoma.
Baptista PF; Fonseca LCM; Carvalho AFC; Silva SNVD; Freitas CRO
Ann Endocrinol (Paris); 2022 Aug; 83(4):258-260. PubMed ID: 35537523
[TBL] [Abstract][Full Text] [Related]
9. Persistent elevation of carcinoembryonic antigen as first presentation of a medullary thyroid carcinoma.
Martins A; Gonçalves A; Almeida T; Midões A
BMJ Case Rep; 2018 Jun; 2018():. PubMed ID: 29895542
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology and Clinical Presentation of Medullary Thyroid Carcinoma.
Raue F; Frank-Raue K
Recent Results Cancer Res; 2015; 204():61-90. PubMed ID: 26494384
[TBL] [Abstract][Full Text] [Related]
11. Calcitonin-negative neuroendocrine tumor of the thyroid: a distinct clinical entity.
Chernyavsky VS; Farghani S; Davidov T; Ma L; Barnard N; Amorosa LF; Trooskin SZ
Thyroid; 2011 Feb; 21(2):193-6. PubMed ID: 21275766
[TBL] [Abstract][Full Text] [Related]
12. Clinical challenges with calcitonin-negative medullary thyroid carcinoma.
Samà MT; Rossetto Giaccherino R; Gallo M; Felicetti F; Maletta F; Bonelli N; Piovesan A; Palestini N; Ghigo E; Arvat E
J Cancer Res Clin Oncol; 2016 Sep; 142(9):2023-9. PubMed ID: 27125958
[TBL] [Abstract][Full Text] [Related]
13. Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma.
Toledo SP; Lourenço DM; Santos MA; Tavares MR; Toledo RA; Correia-Deur JE
Clinics (Sao Paulo); 2009; 64(7):699-706. PubMed ID: 19606248
[TBL] [Abstract][Full Text] [Related]
14. The role of molecular testing in the diagnosis of medullary thyroid cancer: A case report of oncocytic medullary thyroid carcinoma and review of the literature.
Spaulding SL; Ho R; Everest S; Chai RL
Am J Otolaryngol; 2020; 41(1):102312. PubMed ID: 31727331
[TBL] [Abstract][Full Text] [Related]
15. Carcinoembryonic antigen levels correlated with advanced disease in medullary thyroid cancer.
Turkdogan S; Forest VI; Hier MP; Tamilia M; Florea A; Payne RJ
J Otolaryngol Head Neck Surg; 2018 Sep; 47(1):55. PubMed ID: 30223887
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis, treatment, and follow-up of medullary thyroid carcinoma: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism.
Maia AL; Siqueira DR; Kulcsar MA; Tincani AJ; Mazeto GM; Maciel LM
Arq Bras Endocrinol Metabol; 2014 Oct; 58(7):667-700. PubMed ID: 25372577
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic value of selected biochemical markers in the detection of recurrence of medullary thyroid cancer - comparison of calcitonin, procalcitonin, chromogranin A, and carcinoembryonic antigen.
Woliński K; Kaznowski J; Klimowicz A; Maciejewski A; Łapińska-Cwojdzińska D; Gurgul E; Car AD; Fichna M; Gut P; Gryczyńska M; Ruchała M
Endokrynol Pol; 2017; 68(4):434-437. PubMed ID: 28585679
[TBL] [Abstract][Full Text] [Related]
18. Serum Calcitonin-Negative Medullary Thyroid Carcinoma: A Case Series of 19 Patients in a Single Center.
Kim SJ; Yun HJ; Shin SJ; Lee YS; Chang HS
Front Endocrinol (Lausanne); 2021; 12():747704. PubMed ID: 34803914
[TBL] [Abstract][Full Text] [Related]
19. Coexistence of medullary thyroid carcinoma and recurrent non-functional pituitary adenoma: a case report.
Bagherzadeh M; Aminorroaya A; Vafaeimanesh J; Mohajeri-Tehrani MR
J Med Case Rep; 2018 Aug; 12(1):220. PubMed ID: 30107852
[TBL] [Abstract][Full Text] [Related]
20. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.
Mitchell AL; Gandhi A; Scott-Coombes D; Perros P
J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
